Literature DB >> 26154005

Site-specific conjugation improves therapeutic index of antibody drug conjugates with high drug loading.

Pavel Strop1, Kathy Delaria1, Davide Foletti1, Jody Melton Witt1, Adela Hasa-Moreno1, Kris Poulsen1, Meritxell Galindo Casas1, Magdalena Dorywalska1, Santiago Farias1, Ariel Pios1, Victor Lui1, Russell Dushin2, Dahui Zhou2, Thayalan Navaratnam2, Thomas-Toan Tran1, Janette Sutton1, Kevin C Lindquist1, Bora Han3, Shu-Hui Liu1, David L Shelton1, Jaume Pons1, Arvind Rajpal1.   

Abstract

Mesh：

Substances：

Year:  2015        PMID： 26154005     DOI： 10.1038/nbt.3274

Source DB:  PubMed          Journal:  Nat Biotechnol        ISSN： 1087-0156            Impact factor:   54.908


× No keyword cloud information.
  6 in total

1.  Effects of drug loading on the antitumor activity of a monoclonal antibody drug conjugate.

Authors:  Kevin J Hamblett; Peter D Senter; Dana F Chace; Michael M C Sun; Joel Lenox; Charles G Cerveny; Kim M Kissler; Starr X Bernhardt; Anastasia K Kopcha; Roger F Zabinski; Damon L Meyer; Joseph A Francisco
Journal:  Clin Cancer Res       Date:  2004-10-15       Impact factor: 12.531

2.  Location matters: site of conjugation modulates stability and pharmacokinetics of antibody drug conjugates.

Authors:  Pavel Strop; Shu-Hui Liu; Magdalena Dorywalska; Kathy Delaria; Russell G Dushin; Thomas-Toan Tran; Wei-Hsien Ho; Santiago Farias; Meritxell Galindo Casas; Yasmina Abdiche; Dahui Zhou; Ramalakshmi Chandrasekaran; Caroline Samain; Carole Loo; Andrea Rossi; Mathias Rickert; Stellanie Krimm; Teresa Wong; Sherman Michael Chin; Jessica Yu; Jeanette Dilley; Javier Chaparro-Riggers; Gary F Filzen; Christopher J O'Donnell; Fang Wang; Jeremy S Myers; Jaume Pons; David L Shelton; Arvind Rajpal
Journal:  Chem Biol       Date:  2013-02-21

3.  Conjugation site modulates the in vivo stability and therapeutic activity of antibody-drug conjugates.

Authors:  Ben-Quan Shen; Keyang Xu; Luna Liu; Helga Raab; Sunil Bhakta; Margaret Kenrick; Kathryn L Parsons-Reponte; Janet Tien; Shang-Fan Yu; Elaine Mai; Dongwei Li; Jay Tibbitts; Jakub Baudys; Ola M Saad; Suzie J Scales; Paul J McDonald; Philip E Hass; Charles Eigenbrot; Trung Nguyen; Willy A Solis; Reina N Fuji; Kelly M Flagella; Darshana Patel; Susan D Spencer; Leslie A Khawli; Allen Ebens; Wai Lee Wong; Richard Vandlen; Surinder Kaur; Mark X Sliwkowski; Richard H Scheller; Paul Polakis; Jagath R Junutula
Journal:  Nat Biotechnol       Date:  2012-01-22       Impact factor: 54.908

Review 4.  Antibody-drug conjugates: an emerging concept in cancer therapy.

Authors:  Ravi V J Chari; Michael L Miller; Wayne C Widdison
Journal:  Angew Chem Int Ed Engl       Date:  2014-02-20       Impact factor: 15.336

5.  The discovery and development of brentuximab vedotin for use in relapsed Hodgkin lymphoma and systemic anaplastic large cell lymphoma.

Authors:  Peter D Senter; Eric L Sievers
Journal:  Nat Biotechnol       Date:  2012-07-10       Impact factor: 54.908

6.  Contribution of linker stability to the activities of anticancer immunoconjugates.

Authors:  Stephen C Alley; Dennis R Benjamin; Scott C Jeffrey; Nicole M Okeley; Damon L Meyer; Russell J Sanderson; Peter D Senter
Journal:  Bioconjug Chem       Date:  2008-03-04       Impact factor: 4.774
  6 in total
  31 in total

Review 1.  Pharmacokinetic and pharmacodynamic considerations for the next generation protein therapeutics.

Authors:  Dhaval K Shah
Journal:  J Pharmacokinet Pharmacodyn       Date:  2015-09-15       Impact factor: 2.745

2.  Enhancement of antibody functions through Fc multiplications.

Authors:  Qun Wang; Yan Chen; Mark Pelletier; Romana Cvitkovic; Jessica Bonnell; Chien-Ying Chang; Adem C Koksal; Ellen O'Connor; Xizhe Gao; Xiang-Qing Yu; Herren Wu; C Kendall Stover; William F Dall'Acqua; Xiaodong Xiao
Journal:  MAbs       Date:  2017-01-19       Impact factor: 5.857

Review 3.  Strategies and challenges for the next generation of antibody-drug conjugates.

Authors:  Alain Beck; Liliane Goetsch; Charles Dumontet; Nathalie Corvaïa
Journal:  Nat Rev Drug Discov       Date:  2017-03-17       Impact factor: 84.694

Review 4.  Challenges and new frontiers in analytical characterization of antibody-drug conjugates.

Authors:  Anil Wagh; Hangtian Song; Ming Zeng; Li Tao; Tapan K Das
Journal:  MAbs       Date:  2018-01-05       Impact factor: 5.857

5.  Site-Specific Tandem Knoevenagel Condensation-Michael Addition To Generate Antibody-Drug Conjugates.

Authors:  Romas A Kudirka; Robyn M Barfield; Jesse M McFarland; Penelope M Drake; Adam Carlson; Stefanie Bañas; Wes Zmolek; Albert W Garofalo; David Rabuka
Journal:  ACS Med Chem Lett       Date:  2016-08-30       Impact factor: 4.345

Review 6.  Pharmacokinetic Considerations for Antibody-Drug Conjugates against Cancer.

Authors:  Paul Malik; Colin Phipps; Andrea Edginton; Jonathan Blay
Journal:  Pharm Res       Date:  2017-09-18       Impact factor: 4.200

Review 7.  Glycoengineering of Antibodies for Modulating Functions.

Authors:  Lai-Xi Wang; Xin Tong; Chao Li; John P Giddens; Tiezheng Li
Journal:  Annu Rev Biochem       Date:  2019-03-27       Impact factor: 23.643

8.  Overcoming blood-brain barrier transport: Advances in nanoparticle-based drug delivery strategies.

Authors:  Shichao Ding; Aminul Islam Khan; Xiaoli Cai; Yang Song; Zhaoyuan Lyu; Dan Du; Prashanta Dutta; Yuehe Lin
Journal:  Mater Today (Kidlington)       Date:  2020-03-04       Impact factor: 31.041

9.  Site-Specific Antibody Functionalization Using Tetrazine-Styrene Cycloaddition.

Authors:  Benjamin J Umlauf; Kalie A Mix; Vanessa A Grosskopf; Ronald T Raines; Eric V Shusta
Journal:  Bioconjug Chem       Date:  2018-05-03       Impact factor: 4.774

10.  In vivo anti-MUC1+ tumor activity and sequences of high-affinity anti-MUC1-SEA antibodies.

Authors:  Daniel B Rubinstein; Daniel H Wreschner; Edward Pichinuk; Michael Chalik; Itai Benhar; Ravit Ginat-Koton; Ravit Ziv; Nechama I Smorodinsky; Gabi Haran; Christian Garbar; Armand Bensussan; Alan Meeker; Thierry Guillaume
Journal:  Cancer Immunol Immunother       Date:  2020-03-26       Impact factor: 6.968
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.